Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2023)